Study finds one treatment stands above others for adults with Langerhans cell histiocytosis

August 15, 2012

A study by a Baylor College of Medicine physician-researcher has shed light on the most effective treatment for adults with Langerhans cell histiocytosis (LCH) in bones. LCH is a disease that can affect the skin, mouth, ears, bones, brain, gastrointestinal system, liver, spleen, or bone marrow.

In the study, appearing in the current issue of , researchers reviewed for 58 adults with the disease and compared the effectiveness of three chemotherapy treatments – vinblastine/prednisone, 2-Chlorodeoxyadenosine, and cytosine arabinoside.

"Cytarabine (cytosine arabinoside) is clearly the winner here – it's the most effective and least toxic," said Dr. Ken McClain, professor of pediatrics – hematology/oncology at BCM and director of the Histiocytosis Program at Texas Children's Cancer Center.

The study is important because LCH is rare in adults and there is very little research on the disease. There have been no studies in the literature up to now that compare different treatments, according to McClain.

"The No. 1 thing that I hope comes out of this study is that physicians stop using vinblastine/prednisone, which is the least effective and most toxic chemotherapy treatment for this disease," he said.

LCH occurs when white blood cells called histiocytes and lymphocytes gather together and attack the skin, bones, brain, , major organs, mouth and ears. It affects children and adults and can range from a single skin lesion to multi-organ involvement. It can be chronic and debilitating and, in some cases, fatal.

The study reviewed patients who were seen from 2001 to 2011 at BCM. It offers data that could be useful for future clinical trials but, more importantly, it provides literature for physicians who do not know how to treat patients with this rare disease.

Explore further: Leukemia deadlier for teens, young adults than younger kids: study

Related Stories

Leukemia deadlier for teens, young adults than younger kids: study

June 2, 2012
(HealthDay) -- Teenagers and young adults with acute lymphoblastic leukemia, a cancer of the blood and bone marrow, are more likely to relapse and less likely to survive than younger children with the disease, according to ...

Novel treatment for skin lymphoma

January 17, 2012
Promising findings on a novel combination treatment approach for a chronic type of skin lymphoma are being published today (embargoed for 4 pm) in JAMA's Archives of Dermatology by clinical researchers from Seidman Cancer ...

Pediatric regime of chemotherapy proves more effective for young adults

June 18, 2012
Acute lymphoblastic leukemia (ALL), usually found in pediatric patients, is far more rare and deadly in adolescent and adult patients. According to the National Marrow Donor Program, child ALL patients have a higher than ...

The Medical Minute: What is myelodysplastic syndrome?

June 15, 2012
Television journalist and host of "Good Morning America" Robin Roberts announced this week that she has myelodysplastic syndrome, or MDS, an uncommon blood and bone marrow disorder.

Recommended for you

Anti-malaria drug shows promise as Zika virus treatment

November 17, 2017
A new collaborative study led by researchers at Sanford Burnham Prebys Medical Discovery Institute (SBP) and UC San Diego School of Medicine has found that a medication used to prevent and treat malaria may also be effective ...

Decrease in sunshine, increase in Rickets

November 17, 2017
A University of Toronto student and professor have teamed up to discover that Britain's increasing cloudiness during the summer could be an important reason for the mysterious increase in Rickets among British children over ...

Scientists identify biomarkers that indicate likelihood of survival in infected patients

November 17, 2017
Scientists have identified a set of biomarkers that indicate which patients infected with the Ebola virus are most at risk of dying from the disease.

Research team unlocks secrets of Ebola

November 16, 2017
In a comprehensive and complex molecular study of blood samples from Ebola patients in Sierra Leone, published today (Nov. 16, 2017) in Cell Host and Microbe, a scientific team led by the University of Wisconsin-Madison has ...

Study raises possibility of naturally acquired immunity against Zika virus

November 16, 2017
Birth defects in babies born infected with Zika virus remain a major health concern. Now, scientists suggest the possibility that some women in high-risk Zika regions may already be protected and not know it.

A structural clue to attacking malaria's 'Achilles heel'

November 16, 2017
Researchers from The Scripps Research Institute (TSRI) and PATH's Malaria Vaccine Initiative (MVI) have shed light on how the human immune system recognizes the malaria parasite though investigation of antibodies generated ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.